ALT Quote, Financials, Valuation and Earnings

Terns Pharmaceuticals has a net margin of -391500% compared to Altimmune's net margin of --. Altimmune's return on equity of -62.28% beat Terns Pharmaceuticals's return on equity of --.

Altimmune has a consensus price target of $20.63, signalling upside risk potential of 199.21%. On the other hand Terns Pharmaceuticals has an analysts' consensus of $19.14 which suggests that it could grow by 377.38%. Given that Terns Pharmaceuticals has higher upside potential than Altimmune, analysts believe Terns Pharmaceuticals is more attractive than Altimmune.

Altimmune has a beta of 0.581, which suggesting that the stock is 41.857% less volatile than S&P 500. In comparison Terns Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Altimmune has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Terns Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Altimmune pays -- of its earnings as a dividend. Terns Pharmaceuticals pays out -- of its earnings as a dividend.

Altimmune quarterly revenues are $5K, which are larger than Terns Pharmaceuticals quarterly revenues of --. Altimmune's net income of -$19.6M is higher than Terns Pharmaceuticals's net income of -$23.9M. Notably, Altimmune's price-to-earnings ratio is -- while Terns Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altimmune is 24,799.74x versus -- for Terns Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -391500% compared to Altimmune's net margin of --. Altimmune's return on equity of -62.28% beat Theriva Biologics's return on equity of --.

Altimmune has a consensus price target of $20.63, signalling upside risk potential of 199.21%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1398.61%. Given that Theriva Biologics has higher upside potential than Altimmune, analysts believe Theriva Biologics is more attractive than Altimmune.

Altimmune has a beta of 0.581, which suggesting that the stock is 41.857% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.848, suggesting its less volatile than the S&P 500 by 15.165%.

Altimmune has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Altimmune pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Altimmune quarterly revenues are $5K, which are larger than Theriva Biologics quarterly revenues of --. Altimmune's net income of -$19.6M is lower than Theriva Biologics's net income of -$4.3M. Notably, Altimmune's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altimmune is 24,799.74x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of -391500% compared to Altimmune's net margin of --. Altimmune's return on equity of -62.28% beat Viking Therapeutics's return on equity of --.

Altimmune has a consensus price target of $20.63, signalling upside risk potential of 199.21%. On the other hand Viking Therapeutics has an analysts' consensus of $90.26 which suggests that it could grow by 234.8%. Given that Viking Therapeutics has higher upside potential than Altimmune, analysts believe Viking Therapeutics is more attractive than Altimmune.

Altimmune has a beta of 0.581, which suggesting that the stock is 41.857% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.648, suggesting its less volatile than the S&P 500 by 35.236%.

Altimmune has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Altimmune pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Altimmune quarterly revenues are $5K, which are larger than Viking Therapeutics quarterly revenues of --. Altimmune's net income of -$19.6M is higher than Viking Therapeutics's net income of -$45.6M. Notably, Altimmune's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altimmune is 24,799.74x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Y-mAbs Therapeutics has a net margin of -391500% compared to Altimmune's net margin of -24.86%. Altimmune's return on equity of -62.28% beat Y-mAbs Therapeutics's return on equity of -30.14%.

Altimmune has a consensus price target of $20.63, signalling upside risk potential of 199.21%. On the other hand Y-mAbs Therapeutics has an analysts' consensus of $14.70 which suggests that it could grow by 197.57%. Given that Altimmune has higher upside potential than Y-mAbs Therapeutics, analysts believe Altimmune is more attractive than Y-mAbs Therapeutics.

Altimmune has a beta of 0.581, which suggesting that the stock is 41.857% less volatile than S&P 500. In comparison Y-mAbs Therapeutics has a beta of 0.522, suggesting its less volatile than the S&P 500 by 47.821%.

Altimmune has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Y-mAbs Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Altimmune pays -- of its earnings as a dividend. Y-mAbs Therapeutics pays out -- of its earnings as a dividend.

Altimmune quarterly revenues are $5K, which are smaller than Y-mAbs Therapeutics quarterly revenues of $20.9M. Altimmune's net income of -$19.6M is lower than Y-mAbs Therapeutics's net income of -$5.2M. Notably, Altimmune's price-to-earnings ratio is -- while Y-mAbs Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altimmune is 24,799.74x versus 2.49x for Y-mAbs Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.